KNOXVILLE, TN, /Globe Newswire/ -- Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, www.provectusbio.com), ("Provectus" or the "Company"), a clinical-stage biotechnology company developing a novel therapeutic platform based on halogenated xanthenes for the treatment of multiple diseases, including cancer and inflammatory dermatoses, today announced the United States Patent and Trademark Office (the "USPTO") has granted U.S. patent ("USP") 9,839,688 for the combination of intralesional ("IL") PV-10 with systemic immunomodulatory therapy, including anti-PD-1 and anti-PD-L1 agents, for the treatment of solid tumor cancers. This new patent is a continuation of USP 9,107,887, Provectus' first cancer combination therapy patent granted by the USPTO in 2015, and is related to USP 9,808,524, the Company's second cancer combination therapy patent granted by the USPTO in November 2017. Pfizer, Inc. is a co-assignee on all three patents.
Dominic Rodrigues, Chairman of the Company's Board of Directors, said, "This third patent represents our further efforts to increase the potential commercial value of Provectus' clinical development program in cancer combination therapy. Notably, the new addition to this part of the Company's patent estate includes coverage for multiple solid tumor cancers that are already in our research and development pipeline."
Mr. Rodrigues added, "Over time, Provectus and our research and clinical collaborators have jointly or independently shown, on a preclinical or clinical basis, the combination of PV-10 and another class of agent or therapy, including checkpoint inhibition, chemotherapy, and radiation, in multiple cancer indications, including hepatocellular carcinoma, melanoma and pancreatic cancer. These data have been presented at conferences of the Society for Immunotherapy of Cancer and Society for Melanoma Research, and published in the Journal of Surgical Oncology, and Melanoma Research."
Provectus is a clinical-stage biotechnology company leading the development of a new class of drugs based on halogenated xanthenes. Intralesional PV-10, the first small molecule oncolytic immunotherapy, which results in the necrosis of tumor cells and the release of High Mobility Group Box 1, is undergoing clinical study for adult solid tumor cancers like melanoma and cancers of the liver, and preclinical study for pediatric cancers. Topical PH-10 is undergoing clinical study for inflammatory dermatoses like psoriasis; pathways significantly improved by PH-10 treatment include published psoriasis transcriptomes and cellular responses mediated by IL-17, IL-22 and interferons. Information about the Company's clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus, please visit the Company's website at www.provectusbio.com.
FORWARD-LOOKING STATEMENTS: This release contains "forward-looking statements" as defined under U.S. federal securities laws. These statements reflect management's current knowledge, assumptions, beliefs, estimates, and expectations and express management's current views of future performance, results, and trends and may be identified by their use of terms such as "anticipate," "believe," "would," "could," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will," and other similar terms. Forward-looking statements are subject to a number of risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements. Readers should not place undue reliance on forward-looking statements. Such statements are made as of the date hereof, and we undertake no obligation to update such statements after this date.
Risks and uncertainties that could cause our actual results to materially differ from those described in forward-looking statements include those discussed in our filings with the Securities and Exchange Commission (including those described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2016).
Provectus Biopharmaceuticals, Inc.
Tim Scott, Ph.D.